Examination of Hypoxanthine Guanine Phosphoribosyltransferase as a biomarker for colorectal cancer patients

References

• American Cancer Society. Cancer facts & figures 2015. Cancer Facts Fig. 2015;2015:1–9.
   Google Scholar
• Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N. 2012. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep. 28:1301–1308. doi:10.3892/or.2012.1910.
   PubMed Web of Science ®Google Scholar
• Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230. 309-318-321. doi:10.1097/00000658-199909000-00004.
   PubMed Web of Science ®Google Scholar
• Lynch HT. 030306 hereditary colorectal cancer. Color Cancer. 2003;348:919–932. [Internet]. http://www.med.upenn.edu/gastro/documents/NEJMhereditarycolorectalcancer.pdf
   Google Scholar
• Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. 1993. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer. 71:3827–3838. doi:10.1002/(ISSN)1097-0142.
   PubMed Web of Science ®Google Scholar
• Leibovitz A, Stinson JC, McCombs III WB, Mccoy CE, Mazur KC, Mabry ND. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 1976;36:4562–4569. [Internet]. www.ncbi.nlm.nih.gov/pubmed/1000501
   PubMed Web of Science ®Google Scholar
• Vasen HFA, Watson P, Mecklin JP, Lynch HT. 1999. New clinical criteria for Hereditary Nonpolyposis Colorectal Definition (HNPCC, Lynch Syndrome) proposed by the international collaborative group on HNPCC. Gastroenterol. 116:1453–1456. doi:10.1016/S0016-5085(99)70510-X.
   PubMed Web of Science ®Google Scholar
• Schneider M, Huber J, Hadaschik B, Siegers GM, Fiebig -H-H, Schüler J. 2012. Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer. 12:96. doi:10.1186/1471-2407-12-96.
   PubMed Web of Science ®Google Scholar
• Becerra AL. 1998. The role of gene duplication in the evolution of purine nucleotide salvage pathways. Origins of life and evolution of the biosphere. 28:539–553.
   Google Scholar
• Stout JT, Caskey CT. 1985. HPRT: gene structure, expression, and mutation. Annual Reviews Genetics. 19:127–148.
   Google Scholar
• Mummaneni P, Yates P, Simpson J, Rose J, Turker MS. 1998. The primary function of a redundant Sp1 binding site in the mouse aprt gene promoter is to block epigenetic gene inactivation. Nucleic Acids Res. 26:5163–5169. doi:10.1093/nar/26.22.5163.
   PubMed Web of Science ®Google Scholar
• Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A. 2003. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol. 10:513–519. doi:10.1038/nsb942.
   PubMedGoogle Scholar
• Wilson JM, Tarr GE, Kelley WN. 1983. Human hypoxanthine (guanine) phosphoribosyltransferase; an amino acid substitution in a mutant form of the enzyme isolated from a patient with gout. proc Natl Acad Sci USA. 80:870–873.
   Google Scholar
• Nyhan EL. 2008. Lesch-Nyhan Disease. Nucleosides, Nucleotides and Nucleic Acids. 27: 6–7, 559–563.
   Google Scholar
• Zoref-Shani E, Feinstein S, Frishberg Y, Bromberg Y, Sperling O. 2000. Kelley-Seegmiller syndrome due to a unique variant of hypoxanthine-guanine phosphoribosyltransferase: reduced affinity for 5-phosphoribosyl-1-pyrophosphate manifested only at low, physiological substrate concentrations. Biochim Biophys Acta Mol Basis Dis. 1500:197–203. doi:10.1016/S0925-4439(99)00103-9.
   PubMed Web of Science ®Google Scholar
• Torres RJ, Puig JG. 2007. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: lesch-nyhan syndrome. Orphanet J Rare Dis. 2:48. doi:10.1186/1750-1172-2-48.
   PubMed Web of Science ®Google Scholar
• Kostalova E, Pavelka K, Vlaskova H, Musalkova D, Stiburkova B. Clinica Chimica Acta Corrigendum to “ Hyperuricemia and gout due to de fi ciency of hypoxanthine – guanine phosphoribosyltransferase in female carriers : new insight to differential diagnosis. Clin Chim Acta. 2015;447:121. [Internet]. Elsevier B.V. doi:10.1016/j.cca.2015.04.018.
   Web of Science ®Google Scholar
• Jones PA, Taylor SM, Mohandas T, Shapiro LJ. 1982. Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine. Proc Natl Acad Sci U S A. 79:1215–1219. doi:10.1073/pnas.79.4.1215.
   PubMed Web of Science ®Google Scholar
• Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 2007;10:13–29. doi:10.1016/j.drup.2007.01.003.
   PubMed Web of Science ®Google Scholar
• Kaziro Y, Itoh H, Kozasa T, Nakafuku M, Satoh T. 1991. Structure and function of signal-transducing GTPbinding proteins. Annu Rev Biochem. 60:349–400.
   Google Scholar
• Meller M, Vadachkoira S, Luthy DA, Williams MA. 2005. Evaluation of housekeeping genes in placental comparative expression studies. Placenta. 26:601–607. doi:10.1016/j.placenta.2004.09.009.
   PubMed Web of Science ®Google Scholar
• Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, et al. 2009. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 41:619–624. doi:10.1038/ng.370.
   PubMed Web of Science ®Google Scholar
• Liu DW, Chen ST, Liu HP. Choice of endogenous control for gene expression in nonsmall cell lung cancer. Eur Respir J Off J Eur Soc Clin Respir Physiol. 26;2005:1002–1008.
   PubMed Web of Science ®Google Scholar
• Reijm EA, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, van Gelder ME, Sieuwerts AM, Sleijfer S, Foekens JA, Berns EM. 2011. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat. 125:387–394. doi:10.1007/s10549-010-0836-9.
   PubMed Web of Science ®Google Scholar
• Boonstra R, Timmer-Bosscha H, van Echten-Arends J, van der Kolk DM, van den Berg A, de Jong B, Tew KD, Poppema S, de Vries EGE. 2004. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br J Cancer. 90:2411–2417. doi:10.1038/sj.bjc.6601863.
   PubMed Web of Science ®Google Scholar
• Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K, Groettrup M. 2008. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene. 27:6068–6074. doi:10.1038/onc.2008.201.
   PubMed Web of Science ®Google Scholar
• Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, Werb Z, Rosen SD. 2005. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia Neoplasia Press Inc. 7:1001–1010.
   PubMed Web of Science ®Google Scholar
• Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Evans SR. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 53;1993:3712–3718.
   PubMed Web of Science ®Google Scholar
• Alegre MM, Weyant MJ, Bennett DT, Yu JA, Ramsden MK, Elnaggar A, Robison RA, O’Neill KL. 2012. Thymidine kinase 1 upregulation is an early event in breast tumor formation. p. 2012.
   Google Scholar
• Li HX, Lei DS, Wang XQ, Skog S, He Q. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep. 2005;13:145–149. [Internet]. [accessed 2017 Nov 3]. http://www.ncbi.nlm.nih.gov/pubmed/15583816
   PubMed Web of Science ®Google Scholar
• Alegre MM, Weyant MJ, Bennett DT, Yu JA, Ramsden MK, Elnaggar A, et al. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer. Anticancer Res. 2014;34:2145–2152.
   PubMed Web of Science ®Google Scholar
• He E, Xu XH, Guan H, Chen Y, Chen ZH, Pan ZL, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-hodgkin’s lymphoma. Nucleosides Nucleotides and Nucleic Acids. 2010;29:352–358. [Internet]. [accessed 2017 Nov 3]. http://www.ncbi.nlm.nih.gov/pubmed/20544519
   PubMed Web of Science ®Google Scholar
• Alegre MM, Robison RA, O’Neill KL. Thymidine kinase 1: a universal marker for cancer. Cancer Clin Oncol. 2013;2:159–167. [Internet]. http://www.ccsenet.org/journal/index.php/cco/article/view/26281
   Google Scholar
• Townsend MH, Felsted AM, Ence ZE, Piccolo SR, Robison RA, O’Neill KL. Elevated expression of hypoxanthine guanine phosphoribosyltransferase within malignant tissue. Cancer Clin Oncol. 2017;6:19. [Internet]. http://ccsenet.org/journal/index.php/cco/article/view/70556
   Google Scholar
• Townsend MH, Anderson MD, Weagel EG, Velazquez EJ, Weber KS, Robison RA, O’Neill KL. 2017. Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane. Onco Targets Ther. 10:1921–1932. doi:10.2147/OTT.S128416.
   PubMed Web of Science ®Google Scholar
• Sewda K, Coppola D, Enkemann S, Yue B, Kim J, Lopez AS, Wojtkowiak JW, Stark VE, Morse B, Shibata D, Vignesh S, Morse DL. 2016. Cell-surface markers for colon adenoma and adenocarcinoma. Oncotarget. 7:17773–17789. doi:10.18632/oncotarget.7402.
   PubMedGoogle Scholar